Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 | O00206 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.30 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL178385 | 0.87 | CYP1A2 (0.36) | CYP1A2CYP2C9OPRM1OPRK1OPRL1 | |
| SCHEMBL6404417 | 0.86 | CYP1A2 (0.41) | CYP1A2CYP2C9 | |
| SCHEMBL9758125 | 0.86 | TLR4 (0.34) | TLR4CYP1A2 | |
| SCHEMBL9758134 | 0.86 | TLR4 (0.34) | TLR4CYP1A2 | |
| SCHEMBL9758128 | 0.86 | TLR4 (0.34) | TLR4CYP1A2 | |
| SCHEMBL14329914 | 0.84 | TLR4 (0.33) | TLR4 | |
| SCHEMBL9759362 | 0.82 | TLR4 (0.33) | TLR4 | |
| SCHEMBL9759355 | 0.82 | TLR4 (0.33) | TLR4 | |
| SCHEMBL9759349 | 0.82 | TLR4 (0.33) | TLR4 | |
| SCHEMBL5836344 | 0.82 | TLR4 (0.42) | TLR4CYP1A2CYP2C9OPRM1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6864397-B2 | Difluoromethyl ether derivative and process for producing the same | CHISSO CORPORATION (JP) | 2005-03-08 | — | — | US | disclosed |
| US-6827876-B2 | Using alpha, alpha -difluorocyclohexylidene derivative as starting material to obtain difluoromethyl ether derivative | CHISSO CORPORATION (JP) | 2004-12-07 | — | — | US | disclosed |
| US-20040016906-A1 | Difluoromethyl ether derivative and process for producing the same | JNC CORPORATION (JP) | 2004-01-29 | — | — | US | disclosed |
| US-20040004207-A1 | Difluoromethyl ether derivative and process for producing the same | JNC CORPORATION (JP) | 2004-01-08 | — | — | US | disclosed |
| US-6605747-B2 | Reacting the starting material, an alpha , alpha -difluorocyclohexylidene derivative with a halogen to produce an intermediate, reacting the intermediate with a phenol compound in presence of a base | CHISSO CORPORATION (JP) | 2003-08-12 | — | — | US | disclosed |
| US-20020120168-A1 | Difluoromethyl ether derivative and process for producing the same | JNC PETROCHEMICAL CORPORATION (JP) | 2002-08-29 | — | — | US | disclosed |
| EP-1182186-A2 | Difluoromethyl ether derivative and process for producing the same | CHISSO CORPORATION (JP) | 2002-02-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040004207-A1 | Difluoromethyl ether derivative and process for producing the same | RCC1, PYM1, SCFD1 | TLR4 2836/4885CYP1A2 812/4885CYP2C9 1918/4885 |
| US-20040016906-A1 | Difluoromethyl ether derivative and process for producing the same | RCC1, SCFD1, AFF1 | TLR4 2836/4885CYP1A2 821/4885CYP2C9 1877/4885 |
| US-20020120168-A1 | Difluoromethyl ether derivative and process for producing the same | LEF1, AFF1, RCC1 | TLR4 2989/4885CYP1A2 697/4885CYP2C9 1307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.